◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksA › AB

AB Science S.A. (AB) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-16

AB Science S.A. (AB) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Paris, France with about 26 employees. Its market capitalization is roughly €54 million. In the fiscal year ended 2025-12-31, AB reported €1M in revenue and (€2M) in net income.

AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.

Interactive charts & full statements →

AB Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue€1M€1M€1M€1M
Gross Profit€1M€1M€1M€1M
Operating Income (EBIT)€1M(€6M)(€13M)(€16M)
Net Income(€2M)(€8M)(€12M)(€14M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AB Free Cash Flow History

AB Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets€24M€23M€26M€24M
Total Liabilities€42M€47M€46M€60M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AB viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← AAXJAll “A” companiesAB9 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.